Photo Rounds

Hyperpigmented plaque on back

A 69-year-old Black man presented to the Family Medicine Skin Care Clinic with a 4 x 3–cm hyperpigmented, rubbery, micronodular plaque on his left upper back. He reported that the lesion had appeared several years earlier, and noted occasional waxing and waning in size but no associated pain, itching, or trauma to the area. He had a history of hypertension and type 2 diabetes.

What's your diagnosis?


 

References

Hyperpigmented plaque on back

Based on the thickness and size of this irregular lesion, a punch biopsy was performed and confirmed the diagnosis of dermatofibrosarcoma protuberans (DFSP).

DFSPs are usually found on the trunk and proximal extremities; they are most often located on the chest and shoulders. The lesion usually manifests as an asymptomatic, firm, and sometimes nodular plaque that may go undiagnosed for years. DFSP is an uncommon mesenchymal tumor with uncertain etiology. It is thought that prior injury to the affected skin may result in a translocation of chromosomes 17 and 22 in skin cells, as this molecular change characterizes the vast majority of DFSPs.

Black patients are more likely than other ethnic populations to develop DFSP and its variants; there is also a slight female predominance.1 Known variants of DFSP include violaceous plaques with telangiectatic atrophic skin, and plaques with dark brown pigmentation called Bednar tumors.1,2

DFSPs are rarely metastatic, but can be locally invasive, so primary treatment consists of wide local excision or Mohs micrographic surgery (MMS). There is a higher probability for cure when MMS is utilized to treat DFSPs with the added benefit of minimizing surgical margins and preserving healthy surrounding skin. In the rarer cases of advanced local, unresectable, or metastatic disease, inhibitor therapy with imatinib or radiation therapy may be considered.2 Due to the risk of local recurrence, patients with DFSP should have regular clinical follow-up every 6 months for 5 years, followed by annual lifelong surveillance.1

This patient was referred for MMS and has not yet returned for follow-up evaluation.

Photo courtesy of Daniel Stulberg, MD. Text courtesy of Morgan Haynes, BS, University of New Mexico School of Medicine and Daniel Stulberg, MD, FAAFP, Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque.

Recommended Reading

Phase 2 studies of novel JAK1 inhibitor for HS show promise
MDedge Family Medicine
Sarcoidosis
MDedge Family Medicine
More frequent secukinumab dosing found to benefit overweight psoriasis patients
MDedge Family Medicine
Pruritus in elderly patients: Not a diagnosis
MDedge Family Medicine
Sacral blisters
MDedge Family Medicine
Perception of atopic dermatitis severity often differs between patients, physicians
MDedge Family Medicine
New AAD guidelines eye comorbidities in adults with atopic dermatitis
MDedge Family Medicine
A dermatologist-led model for CVD prevention in psoriasis may be feasible
MDedge Family Medicine
Lipedema: A potentially devastating, often unrecognized disease
MDedge Family Medicine
Dryness, conjunctival telangiectasia among ocular symptoms common in rosacea
MDedge Family Medicine